Gene Polymorphism of CYP2B6 and Susceptibility to Acute Myeloid Leukemia in Egypt | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 90, Volume 95, Issue 1, April 2024, Pages 1891-1897 PDF (580.14 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2024.354964 | ||
| Abstract | ||
| Background: Acute myeloid leukemia (AML) is a diverse hematologic neoplasm that is distinguished by aberrant myeloid progenitor cell growth. Genetic factors, including polymorphisms in drug-metabolizing enzymes, such as CYP2B6, have been implicated in AML susceptibility and treatment outcomes. Understanding the association between CYP2B6 gene polymorphisms and AML risk can offer insights into personalized treatment strategies and prognosis. Objective: To ascertain the relationship between CYP2B6 gene polymorphism (rs3745274) and vulnerability to AML in the Egyptian population. Additionally, the study aimed to explore the potential connections between this genetic variation and clinical outcomes, as well as patients' survival. Patients and methods: In the current study, a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique using BseNI restriction enzyme was used to investigate the CYP2B6 rs3745274 gene polymorphism in the peripheral blood and/or bone marrow of 105 AML patients and 111 healthy controls. Results: Based on the study's findings, there was a notable increase in GT, GT+TT genotypes, and T alleles observed in AML patients in contrast to the control group. The statistical analysis indicated that the differences in these polymorphic variants were significant with P-values of 0.018, 0.011, and 0.015, respectively. However, these genetic variations were not associated with any specific FAB subtypes, clinical outcomes, or patients' survival. Conclusion: CYP2B6 rs3745274 gene polymorphism may potentially assist in the emergence of AML. | ||
| Keywords | ||
| AML; SNP; CYP2B6 rs3745274 | ||
|
Statistics Article View: 122 PDF Download: 188 |
||
